Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2007

View Archived Issues

New therapeutic agents for myeloproliferative disorders described in recent Exelixis patent

Recent patents disclose novel treatment options for cardiovascular disorders

Results of phase III studies of galantamine in Alzheimer's disease reported

PKMzeta activity appears necessary for long-term memory maintenance

Ambrilia reports update on clinical trials of prolonged release octreotide

Novel compounds with chaperone activity may be useful in Gaucher's disease

Second generation HCV protease inhibitors described by Schering-Plough

New Akt inhibitors with antitumor potential described by Pfizer

Patient enrollment begins for phase II study of IMC-A12 in advanced prostate cancer

NDA for Merck & Co.'s lipid-modifier, Cordaptive, accepted for review

Memory Pharmaceuticals begins phase I clinical trial of R-4996/MEM-63908

Orexo's treatment for nocturia/incontinence enters phase I

New six-month dosage for MediGene's Eligard receives pan-European approval

Discovery of xanthine-based DPP-IV inhibitor BI-1356 discussed at ACS meeting

Treanda granted U.S. orphan drug designation for CLL

Aspreva and Roche adjust and expand CellCept agreement

GW completes patient recruitment for pivotal phase III trial of Sativex

Baxter and ADCS group agree to initiate phase III study of Gammagard Liquid

Lorus completes proof of concept trial of GTI-2040 for AML; begins phase II trial

Prolexys begins phase I study of PRLX-93936 for solid tumors

Somatuline Depot approved in U.S. for acromegaly

Positive results from phase III study of Vidaza for MDS

Pharming reports positive interim results from phase III trial of Rhucin for HAE

BioDiem begins four studies of BDM-E at Monash University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...